Update on the toxicology and pharmacology of rDSPA alpha 1 (Bat-PA) in animals and humans

Fibrinolysis and Proteolysis

Volumn 11, Issue SUPPL. 2, 1997, Pages 55-62

  Gulba, D C ^a   Praus, M ^a   Dechend, R ^a   Hauck, S ^a   Mahler, M ^b   Zitvz, R ^b   Baldus, B ^b   Muller W ^c   Dietz, R ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b BAYER PHARMA AG   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; DESMODUS ROTUNDUS PLASMINOGEN ACTIVATOR ALPHA1; FIBRINOLYTIC AGENT; PLASMINOGEN ACTIVATOR DERIVATIVE; STREPTOKINASE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGENICITY; BLEEDING TENDENCY; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ELIMINATION; DRUG MECHANISM; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MYOCARDITIS; NEUTROPENIA; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; RAT;

EID: 0030715306     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80071-9     Document Type: Conference Paper

References (29)

1. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected myocardial infarction: ISIS-2. Lancet 1988; ii: 349-360.
2. Gruppo italiano per lo studio della streptochinasi nell'infarto miocardico (GISSI). Long-term effects of intravenous thrombolysis in acute myocardial infarction. Final report of the GISSI Study. Lancet 1987; ii: 871-874.
3. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled trial. Lancet 1988; i: 545-549.
4. Wilcox R G, Von der Lippe G, Olsson C G, et al, and the ASSET Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Lancet 1988; ii: 525-530.
5. Lenderink T, Simoons M L, Van Es G-A, et al, for the European Cooperative Study Group. Benefit of thrombolytic therapy is sustained through five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. Circulation 1995; 92: 1110-1116.
6. The GUSTO Angiographic Investigators. The effect of tissue plasminogen activator, streptokinase, or both on coronaryartery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-1622.
7. Krätzschmar J, Haendler B, Langner G, et al. The plasminogen activator family from salivary gland of the vampire bat Desmodus rotundus: cloning and expression. Gene 1991; 105: 229-237.
8. Gardell S J, Dupe RJ, Diehl R E, et al. Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator. J Biol Chem 1989; 264: 17947-17952.
9. Gulba D C, Praus M, Witt W. DSPA alpha - properties of the plasminogen activator of the vampire bat Desmodus rotundus. Fibrinolysis 1995; 9(Suppl. I): 91-96.
10. Petri T, Baldus B, Boidol W, et al. Novel plasminogen activators from the vampire bat Desmodus rotundus. In: Spier R E, Griffiths J B, MacDonald C, eds. Animal cell technology: Developments, processes and products. European Society for Animal Cell Technology, 1991: 599-604.
11. Witt W, Baldus B, Bringmann P, Schleuning W-D. The new plasminogen activators DSPA-Alpha-1 and Alpha-2 from the vampire bat Desmodus rotundus. Fibrinolysis 1992; 6(Suppl. II): 28 (abstract).
12. Andreotti F, Kluft C, Hackett D R, et al. Thrombin generation after fast or prolonged regimens of tissue-type plasminogen activator or streptokinase induces transient thrombin activity. Lancet 1993; 342: 937-938.
13. Seitz R, Pelzer H, Egbring R. Activation of prothrombin in patients with acute myocardial infarction (AMI) and in vitro by thrombolytic agents. Ann Hematol 1991; 1(Suppl. A): A76 (abstract).
14. Gulba D C, Barthels M, Westhoff-Bleck M, et al. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy. Circulation 1991; 83: 937-944.
15. Gulba D C, Fischer K, Barthels M, et al. Potentiative effect of heparin in thrombolytic therapy of evolving myocardial infarction with natural pro-urokinase. Fibrinolysis 1989; 3: 165-173.
16. Merlini P A, Bauer K A, Oltrona L, et al. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol 1995; 25: 203-209.
17. Rapold H J, de Bono D, Arnold A E R, et al, for the European Cooperative Study Group. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. Circulation 1992; 85: 928-934.
18. Hoffmeister H M, Jur M, Ruf M, et al. Streptokinasetherapie bei akutem Myocardinfarkt führt zur polongierten Aktivierung des Kallikrein-Kininsystems. Z Kardiol 1994; 83(Suppl. 1): A356.
19. Ewald G A, Eisenberg P R. Plasmin-mediated activation of the contact system in response to pharmacological thrombolysis. Circulation 1995; 91: 28-36.
20. Gulba D C, Bode C, Runge M S, Huber K. Thrombolytic agents - an overview. Ann Hematol 1996; 73(Suppl. I): S9-S27.
21. Bringmann P, Gruber D, Liese A, et al. Structural features mediating fibrin selectivity of vampire bat plasminogen activator. J Biol Chem 1995; 270: 25596-25603.
22. Cannon C P, Love T W, McCabe C H, et al, for the TIMI 10 investigators. TNK-tissue plasminogen activator in myocardial infarction (TIMI) 10: results of the initial patients in the TIMI 10 pilot - a phase 1, pharmacokinetics trial. Circulation 1995; 92(Suppl. I): 415 (abstract).
23. Eppler S, Modi N B. Pharmacokinetics of TNK and Activase t-PA in beagle dogs. Genentech report 1994; No. 94-434-0218.
24. Okada K, Lijnen H R, Moreau H, et al. Procoagulant properties of intravenous staphylokinase versus tissue-type plasminogen activator. Thromb Haemost 1996; 76: 857-859.
25. Vanderschueren S, Barrios L, Kerdsinachai P, et al, for the STAR Trial Group. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995; 92: 2044-2049.
26. Heinzel G, Woloszacak W, Thomann P. TOPFIT Version 2.0: Pharmacokinetic and pharmacodynamic data analysis system. Stuttgart, Gustav Fischer, 1993.
27. Tanswell P, Tebbe U, Neuhaus K L, et al. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. J Am Coll Cardiol 1992; 19: 1071-1075.
28. 2Cl and aprotinin for prevention of in vitro effects of recombinant tissue-type plasminogen activator on haemostasis parameters. Thromb Haemost 1987; 58: 921-926.
29. Neuhaus K-L, von Essen R, Tebbe U, et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS). JACC 1991; 19: 885-891.